IL-2 gene therapy for chronic hepatitis B virus infection

Project description

Gene therapy for chronic hepatitis

The hepatitis B virus (HBV) can cause cirrhosis and hepatocellular carcinoma, leading to one million deaths per year worldwide. Since the mechanisms underlying HBV persistence are poorly understood, there is no definitive cure, and current treatments aim to reduce the development of liver disease. The EU-funded 2LIVEr project is working on a novel strategy to reactivate the ineffective CD8+ T cell response towards the HBV based on the hepatocellular delivery of interleukin-2 (IL-2) by lentiviral vectors. This gene therapy approach will serve as a functional cure against chronic hepatitis B by activating the immune system against the virus.

Fields of science

• medical and health sciences › health sciences › infectious diseases › DNA viruses › hepatitis B

Programme(s)

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme

Topic(s)

• ERC-2020-POC - Call for proposals for ERC Proof of Concept Grant

Call for proposal

ERC-2020-PoC

See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Host institution

OSPEDALE SAN RAFFAELE SRL

Net EU contribution

€ 150 000,00

Address

Via Olgettina 60
20132 Milano
Italy

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Non-EU contribution

No data

Region

Nord-Ovest › Lombardia › Milano

Beneficiaries (1)

OSPEDALE SAN RAFFAELE SRL

Italy

Net EU contribution

€ 150 000,00

Address

Via Olgettina 60
20132 Milano

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Non-EU contribution

No data

Region

Nord-Ovest › Lombardia › Milano